Leishmaniasis is a parasitic disease that presents four main clinical syndromes: cutaneous
leishmaniasis (CL), mucocutaneous leishmaniasis (MCL), visceral leishmaniasis/kala azar …

Background and Objectives Visceral leishmaniasis (VL) is a common complication in AIDS
patients living in Leishmania-endemic areas. Although antiretroviral therapy has changed …

It is important to realize that leishmaniasis guidelines cannot always account for individual
variation among patients. They are not intended to supplant physician judgment with respect …

Mycetoma is a chronic granulomatous disease. It is classified into eumycetoma caused by
fungi and actinomycetoma due to filamentous actinomycetes. Mycetoma can be found in …

Visceral Leishmaniasis (VL) is an important protozoan opportunistic disease in HIV patients
in endemic areas. East Africa is second to the Indian subcontinent in the global VL caseload …

Background In the Indian subcontinent, about 200 million people are at risk of developing
visceral leishmaniasis (VL). In 2005, the governments of India, Nepal and Bangladesh …

INTRODUCTION Visceral leishmaniasis (VL) is a neglected disease, with territorial
expansion and regional differences in Brazil that require explanation. This study aimed to …

Background Leishmaniasis is increasingly reported among travellers. Leishmania species
vary in sensitivity to available therapies. Fast and reliable molecular techniques have made …

Background New frontier settlements across the Amazon Basin pose a major challenge for
malaria elimination in Brazil. Here we describe the epidemiology of malaria during the early …

There is an urgent requirement for safe, oral and cost-effective drugs for the treatment of
visceral leishmaniasis (VL). We report that delamanid (OPC-67683), an approved drug for …